Search
10X Genomics Inc
TXGAdd to Watchlist
85.710USD
+1.600+1.90%
Close 09-25 16:00（ET）
10.88BMarket Cap
LossP/E TTM
10X Genomics Inc (TXG) Stock Price Target & Forecast
Analyst Rating
Based on 17 analysts giving stock ratings to 10X Genomics Inc in the past month.
Buy
4 Strong Buy
2 Buy
11 Hold
0 Sell
0 Strong Sell
Target Price
57.071USD-32.15%
TXG Analyst Recommendation Trends
In the current month, TXG has received 2 Buy Ratings, 11 Hold Ratings, and 0 Sell Ratings. TXG average Analyst price target in the last month is 57.071.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
4
4
4
4
4
4
3
2
2
2
2
2
2
2
2
2
11
10
10
11
12
12
13
13
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
17
16
16
17
18
18
18
17
TXG Analyst Rating for Peer Comparison
Updated: Sep 25, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Stryker Corp
SYK
11
13
6
0
0
30
Medtronic PLC
MDT
9
10
11
0
0
30
Dexcom Inc
DXCM
13
13
4
0
0
30
Zimmer Biomet Holdings Inc
ZBH
2
6
21
0
0
29
Medline Ord Shs Class A
MDLN
10
12
6
0
0
28
Abbott Laboratories
ABT
11
12
5
0
0
28
Insulet Corp
PODD
7
8
12
0
0
27
Guardant Health Inc
GH
12
13
2
0
0
27
Repligen Corp
RGEN
5
14
3
0
0
22
Tandem Diabetes Care Inc
TNDM
4
8
10
0
0
22
Financial Forecasting
Based on analysts' estimates, TXG EPS is projected to reach -0.258 in FY2026Q3, following reported EPS of -0.138 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.21
-0.29
-0.24
-0.26
-0.22
Actual
-0.13
-0.10
-0.14
--
--
Surprise
+39.81%
+63.99%
+43.36%
--
--
FAQs
What is 10X Genomics Inc's expected revenue for the next quarter?
10X Genomics Inc's expected revenue is 147.70M.
What is 10X Genomics Inc's price target?
Analysts forecast that 10X Genomics Inc's price target is USD 57.07, with the highest forecast at USD 90.00 and the lowest forecast at USD 40.00.
How have 10X Genomics IncTXG's recent earnings per share performed?
The market expectation was USD -0.14, while 10X Genomics IncTXG's earnings per share (EPS) for the previous quarter was USD -0.10. EPS for the next quarter is expected at USD -0.26.
What is the analyst rating for 10X Genomics Inc?
Based on the ratings of 10X Genomics Inc's stock from 17 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.